An Assessment of the Ability of Fentanyl Citrate Nasal Spray to Manage Breakthrough Pain in Cancer Patients.
Status:
Withdrawn
Trial end date:
2018-04-01
Target enrollment:
Participant gender:
Summary
Lazanda is a prescription nasal spray medicine that contains the medicine fentanyl. It is
used to manage breakthrough pain in adults with cancer who are already routinely taking other
opioid pain medicines around-the-clock for cancer pain. Lazanda is started only after taking
other opioid pain medicines and the patient's body has become used to them (opioid tolerant).
The purpose of this study is to assess the ability of Lazanda to control pain during an
episode of breakthrough pain in cancer patients.
Phase:
Phase 4
Details
Lead Sponsor:
James Graham Brown Cancer Center University of Louisville
Collaborators:
James Graham Brown Cancer Center University of Louisville